Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

Clinical trial NCT07244380 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07244380
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

T Lymphoblastic Leukemia/Lymphoma

Start date: 2025-11-28
Primary completion: 2026-09-30
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.